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2Abstract
Aims: Hyperglycaemia, in stroke patients, is associated with worse neurological outcome by
comprimising endothelial cell function and the blood-brain barrier (BBB) integrity. We have
studied the contribution of hyperglycaemia-mediated generation of oxidative stress to these
pathologies and examined whether antioxidants as well as normalisation of glucose levels
following hyperglycaemic insult reverse these phenomena.
Methods: Human brain microvascular endothelial cell (HBMEC) and human astrocyte co-
cultures were used to simulate the human BBB. The integrity of the BBB was measured by
transendothelial electrical resistance (TEER) using STX electrodes and an EVOM resistance
meter while enzyme activities were measured by specific spectrophotometric assays.
Results: After 5 days of hyperglycaemic insult there was a significant increase in BBB
permeability which was reversed by glucose normalisation. Co-treatment of cells with
hyperglycaemia and a number of antioxidants including vitamin C, free radical scavengers
and antioxidant enzymes including catalase and superoxide dismutase mimetics attenuated the
detrimental effects of hyperglycaemia. Inhibition of p38 MAPK and protein kinase C but not
PI3 kinase also reversed hyperglycaemia-induced BBB hyperpermeability. In HBMEC,
hyperglycaemia enhanced pro-oxidant (NAD(P)H oxidase) enzyme activity and expression
which were normalised by reverting to normoglycaemia.
Conclusions: Hyperglycaemia impairs brain microvascular endothelial function through
involvements of oxidative stress and several signal transduction pathways.
3Introduction
Vascular endothelium covers the entire inner surface of all the blood vessels and is
implicated in the regulation of vasomotor tone, cellular trafficking and the local balance
between pro- and anti-inflammatory mediators [1, 2]. Endothelial cells in some organs
differentiate and develop into specialised barriers to regulate vascular permeability. One such
example is the blood-brain barrier (BBB) which stops the passage of substances from blood
into the central nervous system. The BBB consists of brain microvascular endothelial cells
(BMEC), capillary basement membranes and astrocyte end-feet. Astrocytes surround 99% of
the BBB endothelia and release soluble factors to maintain the integrity of the BBB [3]. Since
the brain oedema, associated with the BBB disruption, is more prevalent in stroke patients
with diabetes mellitus than those without, it is safe to suggest that hyperglycaemia plays a
prominent role in this defect [4-6].
Diabetes mellitus is a metabolic disorder associated with microvascular complications.
Although several mechanisms including non-enzymatic glycation of proteins and lipids with
the irreversible formation/deposition of advanced glycation end products (AGEs), the
activation of polyol pathway, stimulation of protein kinase C (PKC) or oxidative stress
accompanied by overproduction of reactive oxygen species (ROS) have been implicated in
peripheral vascular pathologies [1], the mechanisms by which hyperglycaemia exerts damage
on brain microvasculature remain unknown.
The hyperglycaemia-mediated activation of PKC represents a hallmark in peripheral
vasculopathies and is associated with increases in endothelial permeability, angiogenesis and
ROS overproduction [7, 8]. ROS, in particular superoxide anion (O2.-) increase vascular
permeability in various disease models including focal ischaemia and impairs neuronal
homeostasis and cerebrovascular tone [9, 10]. NAD(P)H oxidase, a pro-oxidant enzyme with
a membrane-bound active core consisting of p22-phox and gp91-phox subunits, has been
4shown as the main enzymatic source of ROS in coronary EC exposed to hyperglycaemia [11].
Under physiological conditions, once generated O2.- is neutralised by superoxide dismutases
(SODs) to H2O2 which in turn is metabolised to H2O by catalase and glutathione peroxidase
(GPx).
Nitric oxide (NO), another ROS generated by endothelial NO synthase (eNOS), is also
implicated in diabetic microvasculopathy and BBB hyperpermeability in cerebral pathologies
such as middle cerebral artery occlusion where the NOS inhibitors (L-NNA and L-NAME)
have been shown to reduce both brain oedema and BBB damage [12]. However,
physiological levels of NO are known to regulate cerebral blood flow, vascular tone and
protect against ischaemic stroke by increasing collateral flow to the ischaemic area [13]. It is
of note that endothelial cells represent the main cellular source of NO and O2.- and the
prevalence of diabetes is significantly greater in ischaemic stroke patients with small-vessel
compared to large-artery diseases [14].
It is well-documented that hyperglycaemia promotes a pro-coagulant state to compromise
blood supply to the penumbral areas in acute ischaemic stroke (AIS) through, in part,
increasing the expressions of intercellular adhesion molecule-1 (ICAM-1) and vascular cell
adhesion molecule-1 (VCAM-1) [15].
In the light of the currently available data, this study hypothesises that hyperglycaemia may
perturb endothelial function and the BBB integrity by promoting oxidative stress and
employing a variety of intermediary molecules. To this end, the present study was designed to
investigate whether; i- changes in the expression and/or activities of oxidative stress related
parameters i.e. adhesion molecules and pro- and antioxidant enzymes are involved in
hyperglycaemia-mediated cerebral microvascular endothelial cell dysfunction, ii- exposure of
HBMEC and human astrocytes (HA) co-cultures to normoglycaemia or hyperglycaemia
distinctly modulate blood-brain barrier (BBB) integrity; iii- antioxidants and signal
5transduction pathway inhibitors can help in the maintenance of the BBB integrity during
hyperglycaemic insult; iv- normalisation of glucose levels has favourable effects on the
aforementioned parameters following hyperglycaemic insult.
Materials and Methods
Cell culture
HBMEC and HA were purchased from TCS Cellworks (Buckingham, UK) and cultured in
specialised media. HA were characterised by glial fibrillary acidic protein (GFAP) staining
while HBMEC were characterised by stainings for vWF/Factor VIII and CD31 (P-CAM) as
well as by uptake of DiI-Ac-LDL. Cells were grown to subconfluence and incubated under
normoglycaemic (NG; D-Glucose; 5.5 mM) and hyperglycaemic (HG; D-Glucose; 25 mM)
conditions for a period of five days. Cells were also cultured in equimolar concentrations of
D-Mannitol (25 mM) to assess if the changes observed in enzyme activities or expressions
were due to hyperosmolality rather than HG per se. In a sub-set of experiments HBMEC were
initially cultured in hyperglycaemic conditions for 5 days followed by a further 5 days culture
in normoglycaemic conditions to assess the specific effects of glucose normalisation on
aforementioned oxidative stress-related biomarkers.
Evaluation of cell viability
To detect cytotoxicity of outlined treatment regimens, a small aliquot of cells were
incubated in 0.1% trypan blue for 4 min and viewed under a light microscope. By counting
100 cells, the percentage of viable cells was calculated.
In vitro BBB co-culture model
HA were seeded on the outside of collagen-coated polycarbonate membrane (0.4 μM)
Transwell inserts (12-well type, Corning) directed upside down in the culture chamber. HA
were allowed to adhere to the membrane overnight and then inverted the correct way.
HBMEC were seeded on the inside of the insert and cells were grown to confluence, to create
6the contact co-culture model. The non-contact model is a replica of the contact model but the
astrocytes were seeded onto the bottom of the well as opposed to the underside of the
Transwell insert. Co-cultures were incubated for a period of 72 h under NG, HG and HG in
the presence of an antioxidant agent including vitamin C (0.5 μM), catalase (150 U/mL), a
free radical scavenger (MnTBAP; 50 μM), a protein kinase C inhibitor i.e. bisindolyamide I
(5 μM) or a MAPK inhibitor (SB203580; 10 μM). To investigate the extent of HA
involvement in preservation of the BBB integrity under HG conditions, a monolayer of
HBMEC were exposed to the aforementioned agents.
Measurement of BBB integrity
This was assessed by measuring transendothelial electrical resistance (TEER) across the
membrane using STX electrodes and an EVOM resistance meter (World Precision
Instruments, UK). Three independent readings were taken every 24 hours and blank filter
measurements were subtracted from inserts seeded with cells. Values are shown as Ωcm2
based on culture insert size.
Measurement of NAD(P)H oxidase activity
NAD(P)H oxidase activity was measured by cytochrome C reduction assay. Briefly, an
aliquot of HBMEC homogenates (obtained from 20 x 106 cells by homogenisation of the cell
pellet in cold 20 mM HEPES buffer, pH 7.2, containing 1 mM EGTA, 210 mM mannitol and
70 mM sucrose) was incubated with 50 µM cytochrome C for 60 min at 37°C. O2.- generation
was measured as the superoxide dismutase (10 µg/ml)-inhibitable reduction of cytochrome C
and monitored as the change in absorbance at 550 nm using a GENios plate reader (TECAN).
In order to ascribe all cytochrome C reduction to NAD(P)H oxidase, the specific inhibitors of
other ROS-generating enzymes i.e. L-NAME (100 M, NOS inhibitor), rotenone (50 M,
mitochondrial complex I inhibitor), allopurinol (100 M, xanthine oxidase inhibitor) or
indomethacin (50 M, cyclooxygenase inhibitor) were added simultaneously to aliquots at the
7beginning of 60 min incubation period prior to determining O2.- generation. Absorbances were
recorded for 8 min with 60 sec intervals and activity was calculated as pmoles O2.- per mg
protein following subtraction of background levels at 550 nm.
NOS Assay
NOS activity was determined, in cell homogenates, using the NOSdetect assay kit (Alexis
Biochemicals). Briefly, cells were lysed in buffer containing 25 mM Tris, pH 7.4, 1 mM
EDTA and 1 mM EGTA and centrifuged for 30 min at 4000 g. 10 l supernatant and 40 L
reaction buffer (50 mM Tris, pH 7.4, 6 M tetrahydrobiopeterin, 2 flavin adenine
mononucleotide, 2 flavin adenine dinucleotide, 10 mM NADPH, 6 mM CaCl2) containing
100.000 dpm [3H]L-arginine were combined. Following 30 min incubation at room
temperature, the enzymatic reaction was stopped by the addition of stop buffer (50 mM
HEPES, 5 mM EDTA, pH 5.5). Newly formed [3H]L-citrulline, neutral at pH 5.5, was then
separated from the incubation mixture by cation exchange resin (Dowex AG 50 W-X8) and
quantified using a liquid scintillation counter. The contribution of iNOS to overall NOS
activity was assessed in similar experiments by replacing the calcium in reaction buffer with
EGTA (5 mM). Data were normalised by the amount of protein and reaction time. Results
were expressed as pmol L-citrulline/mg protein/min.
Nitrite Detection
Nitrite levels were measured by Griess reaction as an index of NO generation following
conversion of nitrate to nitrite by nitrate dehydrogenase. Cellular homogenate was mixed with
an equal volume of Griess reagent (sulfanilamide 1% w/v, naphthylethylenediamine
dihydrochloride 0.1% w/v and orthophosphoric acid 2.5% v/v) and incubated at room
temperature for 10 min prior to measurement of absorbances at 540 nm. Nitrite formed was
compared to those of known concentrations of sodium nitrite and normalised according to the
protein concentration.
8SOD Assay
SOD activity was measured by detecting the level of variation in O2.- levels using a
tetrazolium salt. Untreated and treated HBMEC homogenates were diluted 1:20 with radical
detector and assayed in triplicate in a 96-well ELISA plate (Calbiochem). Reactions were
initiated by the addition of 20 µl diluted xanthine oxidase to generate O2.- and the plate was
incubated on a shaker for 20 min at room temperature. Absorbances were read at 450 nm and
total SOD activity was determined using the equation obtained from the linear regression of
the SOD standard curve. One unit of SOD was defined as the amount of enzyme needed to
exhibit 50% dismutation of the O2.- (kit range 0.025-0.25 units/ml). MnSOD activity was
detected following inhibition of CuZnSOD activity via incubation with 3 mM potassium
cyanide (BDH Chemicals Ltd, UK), at room temperature for 45 minutes. CuZnSOD activity
was subsequently calculated by the subtraction of MnSOD activity from total SOD activities.
Catalase Assay
Catalase activity was measured using an immunoassay kit (Merck Biosciences, UK). The
assay was based on the reaction of catalase with optimal concentration of H2O2 in the
presence of methanol to produce formaldehyde and detect it spectrophotometrically using 4-
amino-3-hydrazino-5-mercapto-1,2,4-triazole (Purpald) as the chromogen. Enzyme activities
were then determined using a standard curve generated with formaldehyde. One unit was
defined as the amount of enzyme that generates the formation of 1 nmol formaldehyde per
min, at 25 °C.
GPx Assay
GPx activity was measured using a specific immunoassay kit (Merck Biosciences, UK)
based on the simultaneous reduction of glutathione and oxidation of NAD(P)H to NADP+,
accompanied by a decrease in absorbance at 340 nm. GPx activities were then calculated
9using the extinction coefficient for NAD(P)H at 340 nm (0.00373 µM-1). One unit of GPx was
defined as the activity that converts 1 mM of reduced glutathione per litre per min, at 25oC.
Cellular Adhesion Molecule Assays
ICAM-1 and VCAM-1 concentrations were determined using quantitative sandwich
enzyme immunoassay kits (R&D Systems, UK) and microplates pre-coated with monoclonal
antibodies specific for the markers in question, as per manufacturer’s instructions. Sample
absorbances were read at 450 nm and subtracted from readings taken at 540 nm or 620 nm for
VCAM-1 and ICAM-1, respectively. Concentrations were then calculated from a standard
curve of known values.
Western Blotting
Total cellular proteins were isolated by lysis and equal amounts of protein (50 μg) were run
on 10% SDS-polyacrylamide gels. Proteins were transferred to nitrocellulose membranes
prior to overnight incubation with monoclonal primary antibodies. Primary antibodies to
catalase, MnSOD, CuZnSOD and GPx were obtained from Merck Biosciences. eNOS was
from Transduction Laboratories while those for gp91-phox and p22-phox were from Autogen
Bioclear. Horseradish peroxidase linked secondary antibodies were then used and the bands
were detected by enhanced chemiluminescence (GE Healthcare). Blots were assessed by
densitometry of bands with subtraction of the background counts measured outside loaded
lanes.
Statistical Analysis
Results of molecular assays and TEER experiments are presented as mean  SEM.
Statistical analyses were performed by two-way analysis of variance (ANOVA) followed by
Bonferroni-Dunn’s post hoc analysis and p<0.05 was considered significant.
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Results
Effects of hyperglycaemia on protein expression
HG produced significant increases in p22-phox, a subunit of NAD(P)H oxidase, eNOS,
CuZnSOD, catalase and GPx protein expression in HBMEC without affecting that of
MnSOD. Glucose normalisation following HG significantly decreased p22-phox, eNOS,
catalase, and GPx protein levels (Figure 1).
Effects of hyperglycaemia on pro-oxidant and antioxidant enzyme activities
Exposure of HBMEC to HG for 5 days resulted in a 2-fold increase in pro-oxidant
NAD(P)H oxidase enzyme activity compared to cells grown under normoglycaemic
conditions. Normalisation of glucose levels for a further 5-day period attenuated the effects of
the hyperglycaemic insult (Table 1).
Similar to NAD(P)H oxidase, the eNOS activity and nitrite levels, a breakdown product of
NO production, also rose in HBMEC cultured under hyperglycaemic conditions which were
subsequently reduced by glucose normalisation (Table 1).
HG significantly enhanced CuZnSOD activity in HBMEC that was diminished by glucose
normalisation where MnSOD activity appeared to be unaffected by HG (Table 1).
Catalase activity was found to be significantly increased in hyperglycaemic HBMEC that
was diminished with glucose normalisation. Although hyperglycaemia produced a slight
increase in GPx activities, glucose normalisation caused a profound decrease in its activity
(Table 1).
Effects of hyperglycaemia on adhesion molecules
HG produced a significant increase in VCAM-1 but not ICAM-1 concentration. Glucose
normalisation had no effect on ICAM-1 levels while significantly decreasing that of VCAM-1
compared to the HG group (Figure 2).
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Effects of different treatment regimens on cellular viability
No significant variations were observed in overall viability rates of HBMEC and HA
cultured with HG, NG or hyperosmolar media (Table 2).
Effects of hyperglycaemia on TEER
As HA-HBMEC co-cultures produced better electrical resistance compared to non-contact
and HBMEC monolayer models, this model has been used throughout the study to obtain
statistically significant differences (Figure 3). HG induced a marked decrease in TEER
compared to D-mannitol and NG treatment groups thereby inferring an increase in BBB
permeability via disruption of the BBB where reversal of glucose to normal levels for 72 h
restored BBB integrity (Figure 4). Treatment of cells with a wide range of antioxidants,
namely an NAD(P)H oxidase inhibitor (apocynin; 500 μM), vitamin C (0.5 μM), a free
radical scavenger (mercaptopropionylglycine (MPG); 0.5 μM), an antioxidant enzyme
(catalase; 25-150 U/ml) and two different SOD mimetics (MnTBAP; 50 μM or
Mn(III)TMPyP; 10 μM) restored HG-mediated decreases in TEER (Figure 5).
Other studies employing specific inhibitors of protein kinase C (Bisindolyamide I, 5 μM)
and p38MAPK (SB203580, 10 μM) and PI3 kinase (LY29402, 50 μM) have shown that
selective inhibitions of protein kinase C and p38MAPK but not PI3 kinase reverses HG-
induced decreases in TEER readings (Figure 6).
Discussion
The major conclusions to be drawn from this study are that hyperglycaemia compromises
the BBB integrity through mechanisms mediated, in part, by oxidative stress and different
signal transduction pathways. Indeed, specific inhibition of PKC or p38MAPK pathways,
alleviation of oxidative stress by a series of functionally distinct antioxidants and
normalisation of high glucose levels restore the BBB integrity.
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Diabetes mellitus (DM) is a major risk factor for ischaemic stroke while hyperglycaemia
without pre-existing diabetes is linked to a worse neurological outcome and stroke mortality
[9, 16]. Brain oedema constitutes one of the main causes of death following stroke and is
associated with the BBB disruption. Considering that the brain oedema is more prevalent in
stroke patients with DM than those without, it is reasonable to suggest that HG plays a
prominent role in this defect [4-6]. Ischaemic stroke develops through an interference with
blood supply to the central nervous system and may be associated with oxidative stress i.e. an
imbalance between ROS production and metabolism [17]. Although low level generation of
ROS is critical for neuronal homeostasis, their excess generation, particularly by NAD(P)H
oxidase, is implicated in vascular injuries and intracranial haemorrhage [18, 19]. Increases in
certain NAD(P)H oxidase subunit expressions have been shown in STZ-induced diabetic rats
with transient middle cerebral artery occlusion, an animal model of human ischaemic stroke
and correlated with infarct sizes, more severe neurological deficits and brain oedema volume
[20]. Significant increases in NAD(P)H oxidase enzyme activity and p22-phox protein
expression, an integral NAD(P)H subunit, have also been found in this study in HBMEC
cultured under hyperglycaemic conditions. Given that these increases were suppressed by
normalisation of glucose levels, collectively these data shed some light on the mechanistic
causes of HG-mediated increases of oxidative stress and subsequent endothelial dysfunction.
As deficiencies in MnSOD and/or CuZnSOD activities may also contribute to enhanced
oxidative status, the expression and activities of these enzymes were explored in HBMEC
exposed to HG which revealed no changes or significant increases in cases of MnSOD and
CuZnSOD, respectively. Since HG significantly increases the BBB permeability, these data
imply that the increase in CuZnSOD activity (~2-fold) which makes up ~80% of total SOD
activity [21] is not sufficient to quench the excessive ROS generated under hyperglycaemic
conditions. In support of this hypothesis, the current study has shown that the concurrent
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employment of HG with one of the two structurally different SOD mimetics i.e. MnTBAP or
Mn(III)TMPyP attenuates BBB hyperpermeability. Higher rates of increases in CuZnSOD
has previously been shown to diminish HG-enhanced brain oedema and Evans blue leakage in
heterozygous SOD1 Tg rats carrying human SOD1 genes to achieve 4- to 6-fold increase in
CuZnSOD [22]. It is of note that while normalisation of glucose levels effectively suppressed
CuZnSOD activity, it had no effect on its protein expression. A compensatory response to
increase subdued enzyme activity by de novo protein synthesis in order to neutralise still
considerably high quantities of O2.- during normoglycaemic phase following a
hyperglycaemic insult may, in part, account for this phenomenon.
Once dismutated O2.- forms H2O2 which requires further breakdown to H2O by antioxidant
enzymes catalase and GPx. This study has shown significant increases in catalase activity and
protein expression in HBMEC exposed to HG which were reversed by glucose normalisation
and consequent removal of HG-mediated oxidative insult. Similar to catalase, a slight but
significant increase was also observed in GPx protein expression in cells cultured under
hyperglycaemic conditions. However, the increase in protein levels was not translated into
activity perhaps as a result of previously reported instability of the GPx complex over time in
diabetic rat tissues including brain [23].
NO, another ROS, has also been implicated in the BBB hyperpermeability in cerebral
pathologies such as middle cerebral artery occlusion [12]. It is mainly generated by
endothelial NO synthase (eNOS) whose activity and expression under diabetic conditions
remain controversial in that both enhanced and diminished eNOS expressions have been
reported in diabetic patients, animal models and also in cells cultured with high
concentrations of glucose [24, 25]. However, similar to a previous study showing substantial
elevations in STZ-induced diabetic rat hippocampus, cortex, cerebellum, brain stem and
spinal cord [26], the current study has also revealed considerable increases in both eNOS
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enzyme activity and nitrite levels in HBMEC subjected to HG which were attenuated by
glucose normalisation. Although these findings may suggest a possibility that, in contrast to
peripheral organs eNOS may be regulated in a similar manner by HG in different parts of the
central nervous system, this hypothesis requires further detailed investigations.
Endothelial dysfunction is in part regulated by the expression of adhesion molecules
such as ICAM-1 and VCAM-1 on the surface of ECs. Results from this study demonstrate
that VCAM-1 but not ICAM-1 concentrations are increased under HG conditions which are
dramatically decreased by glucose normalisation. Similar to our study, Haubner et al have
also reported a glucose-specific increase in the basal expression of membrane-bound VCAM-
1 but not ICAM-1 and E-Selectin [27]. Conversely, a recent in vivo study has shown that the
numbers of ICAM-1 positively stained microvessels in the cortex were markedly increased at
3 days of reperfusion in diabetic but not in non-diabetic rats, suggesting that inflammatory
responses mediate HG-aggravated brain damage, induced by ischaemia and reperfusion [28].
Although the reasons behind the differences between in vitro and in vivo studies require
exploration, development of intracerebral diabetic ketoacidosis may in part account for this
dichotomy. Indeed, an in vitro study with increasing concentrations of glucose along with
acetoacetate and -hydroxybutyrate led to increased expression of ICAM-1 and perturbed
membrane function [29].
It is well-documented that the integrity of the BMEC layer is critical for BBB function as a
whole and pathological conditions including HG may compromise this tight continuum
through facilitating the formation of openings in transcellular or paracellular pathways.
Hence, the last phase of the current study examined the alterations in BBB permeability under
hyperglycaemic versus normoglycaemic conditions via TEER measurements. As static
monolayer and non-contact co-culture models did not produce significant variations in TEER,
contact co-cultures have been used throughout the study. The current study has shown that
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HG exerted a significant decrease in TEER, a reliable indicator of the BBB integrity which
was blocked by a series of antioxidants with unique mechanisms of action thereby proving
oxidative stress as a key player in the pathogenesis of this defect. The antioxidant compounds
used in the study were vitamin C (an antioxidant vitamin), apocynin (a specific inhibitor of
NAD(P)H oxidase), MPG (O2.- scavenger), MnTBAP and Mn(III)TMPyP (SOD mimetics),
catalase (an antioxidant enzyme) and Bis-I and SB203580 (protein kinase C and p38MAPK
inhibitors, respectively). These findings were in agreement with previous studies showing that
SOD and catalase administrations reduce the tracer permeation to the cerebral ischemic brain
in rats [30-32].
The findings with the PKC inhibitor were, to a large degree, expected considering
undisputed involvement of PKC activation in hyperglycaemia-mediated peripheral
vasculopathies, ROS overproduction and cerebral endothelial dysfunction [7, 8, 33]. Protein
kinase C may utilise two mechanisms to impair NO-mediated vasodilatation. Firstly, it may
directly modify eNOS post-translationally via its dephosphorylation at Ser1177 and
phosphorylation at Thr495 which together result in decreased NO production [34]. Secondly,
protein kinase C may impair eNOS function indirectly through effects on NAD(P)H oxidase,
the most potent generator of O2.- that rapidly scavenges NO. Similar to PKC, inhibition of
p38MAPK has also been shown as neuroprotective in cerebral ischaemia [35, 36]. The p38
pathway may mediate neuronal damage by counteracting ERK signalling in models of
apoptosis and free radical damage in vitro [38], by controlling the release of granules in
neutrophils in the process of inflammation [39] or by induction of cytokines [40]. However,
contradictory reports with p38MAPK inhibitor also exist in that rats given SB203580 prior to
transient middle cerebral artery occlusion have been shown to develop widespread cerebral
lesions and vascular leakage [37].
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Research encompassing the PI3K inhibitor, LY29402 is very limited. However, Gottfried et
al reported loss of polygonal morphology with varying degrees of stellation in rat
hippocampal astrocytes treated with LY29402 [41]. This may have significance as intact brain
astrocytic processes encounter and bind to collagen IV and laminin in the basement
membrane of endothelial cells that surround cerebral capillaries and form the BBB [42].
Concurrence between previously published data and our findings suggest that the potential
therapies for hyperglycaemia in acute stroke patients should include treatment regimens that
establish and maintain normoglycaemia. In support of this notion, a recent retrospective study
of AIS patients showed that patients with an admission glucose level of >130mg/dl had
increased mortality compared to those whose glucose levels were normalised within 48 hr
[43]. In this context, another study has revealed that intensive intravenous insulin therapy to
maintain NG reduce the risk of organ failure and death in surgical intensive care patients [44].
In conclusion the current study has shown that HBMEC incubated with HG possess
enhanced NAD(P)H oxidase enzyme activity and expression compared to cells grown under
NG and that the reversal of HG to NG significantly suppress these increases. Secondly the
increased production of free radicals by NAD(P)H oxidase through activation of different
signal transduction pathways appear to compromise the integrity of the BBB under diabetic
conditions. Effective reversal of high glucose levels exerts beneficial effects on the
preservation of the BBB unity and may therefore be therapeutically beneficial in diabetic
stroke patients.
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Figure legends
Fig. 1 (A) Representative Western blots of pro-oxidant (p22-phox) and anti-oxidant proteins
in human brain microvascular endothelial cells (HBMEC) cultured under hyperosmolality
(lane 1; 25mM D-mannitol), normoglycaemia (lane 2; 25mM D-Glucose), hyperglycaemia
(lane 3; 25 mM D-Glucose) and hyperglycaemia followed by normoglycaemia (lane 4) for a
period of 5 days. (B) Histograms showing fold-differences in anti-oxidant and pro-oxidant
protein expressions in HBMEC exposed to HG versus NG or HG/NG. Data are expressed as
mean ± SEM from 3 different experiments. *p<0.05 HG vs NG. #p<0.05 HG vs HG/NG.
Fig. 2 The effects of hyperglycaemia (25mM D-Glucose) and glucose normalisation on
human brain microvascular endothelial cell expression intercellular adhesion molecule-1
(ICAM-1; A) and vascular cell adhesion molecule-1 (VCAM-1, B) following 5 days of
treatment. Data are expressed as mean ± SEM from 5 different experiments. *p<0.05
compared to NG (5 mM D-Glucose). #p<0.05 compared to HG (25mM D-Glucose).
Fig. 3 (A) Schematic diagram of the in vitro models of the BBB and corresponding readings
of transendothelial electrical resistance readings (TEER; B). (1) Control, (2) Human brain
endothelial cell (HBMEC), (3) Human astrocyte (HA) and HBMEC non-contact (4) HA and
HBMEC contact cultures. Data are expressed as mean ± SEM from 5 different experiments.
*p<0.05 compared to non-contact model.
Fig. 4 Effects of hyperosmolality (25mM D-mannitol), normoglycaemia (5.5.mM D-
Glucose), hyperglycaemia (25mM D-Glucose) and hyperglycaemia followed by
normoglycaemia on BBB permeability. Data are expressed as mean ± SEM from 5 different
experiments. *p<0.05 compared to NG (5 mM D-Glucose). #p<0.05 compared to HG (25mM
D-Glucose).
Fig. 5 Effects of antioxidants, apocynin (500 μM), vitamin C (0.5 μM), MPG (0.5 μM), and
superoxide dismutase mimetic MnTBAP (50 μM) and Mn(III)TMPyP (10 μM) and catalase
23
(25 and150 U/mL) on transendothelial electrical resistance (TEER) readings. Data are
expressed as mean ± SEM from 5 different experiments. *p<0.05 compared to NG (5 mM D-
Glucose). #p<0.05 compared to HG (25mM D-Glucose).
Fig. 6 Effects of protein kinase C (Bisindolyamide I, 5 μM), p38MAPK (SB203580, 10 μM)
and PI-3 kinase (LY29402, 50 μM) inhibitors on transendothelial electrical resistance
(TEER). Data are expressed as mean ± SEM from 6 different experiments. *p<0.05 compared
to NG (5.5mM D-Glucose). #p<0.05 compared to HG (25mM D-Glucose).
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Figure 6.
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Table 1. The effects of hyperglycaemia and glucose normalisation on prooxidant NAD(P)H oxidase and antioxidant enzyme activities.
Treatment Group
NAD(P)H Oxidase
(pmole O2.- mg protein)
eNOS
(pmole L-citrulline/mg
protein/min)
CuZnSOD
(mU/mg protein)
MnSOD
(mU/mg protein)
GPx
(nmol/min/mL)
Catalase
(nmol/min/mL)
Nitrite
(μM)
D-Mannitol 25mM 0.042 ± 0.007 13415.9 ± 886.5 278 ± 46 12 ± 1 64.09 ± 6.61 22.13 ± 1.97 10.44 ± 0.67
D-Glucose 5.5mM 0.045 ± 0.007† 12952.8 ± 924.4 290 ± 37† 24 ± 6 53.40 ± 4.88 21.94 ± 0.59 6.73 ± 0.86
D-Glucose 25mM 0.100 ± 0.006* 17361.4 ± 1414.9* 428 ± 39* 22 ± 3 58.92 ± 6.40 27.00 ± 1.56* 13.44 ± 0.24*
D-Glucose 25/5.5mM 0.067 ± 0.005*† 15720.6 ± 277.9*† 209 ± 26*† 7 ± 4*† 21.83 ± 5.40*† 10.36 ± 1.22*† 10.77 ± 0.37*†
The levels of enzyme activities were measured in human brain microvascular endothelial cells (HBMEC) cultured with a hyperosmolality control (D-Mannitol 25mM),
normal glucose (D-Glucose 5.5mM), high glucose (D-Glucose 25mM) and high glucose followed by normal glucose for a period of 5 days. Data are expressed as mean ±
SEM from 5 different experiments. *p<0.05 compared to NG (D-Glucose 5.5mM). †p<0.05 compared to HG (D-Glucose 25mM).
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Table 2. Effects of hyperosmolality, normoglycaemia, hyperglycaemia and hyperglycaemia followed by normoglycaemia on HBMEC and HA
viability.
Treatment Group HBMEC HA
D-Mannitol 25mM 86 ± 4 91 ± 4
D-Glucose 5.5mM 93 ± 5 90 ± 7
D-Glucose 25mM 89 ± 2 88 ± 5
D-Glucose 25/5.5mM 90 ± 7 87 ± 6
Percentage viable cells were determined by trypan blue exclusion experiments and counting 100 cells. Data are expressed as mean ± SEM from
3 different experiments.
